Articles
A national drug shortage of mechlorethamine has been linked to a higher rate of relapse among children, teenagers, and young adults with Hodgkin lymphoma enrolled in a national clinical trial.
For those who have been affected by cancer, the holidays can be stressful and anxiety-ridden.
A recent study has determined that chronic obstructive pulmonary disease (COPD) is not an independent risk factor for lung cancer.
Results from a retrospective analysis of more than 36,000 individuals with colon cancer indicated that patients with early-stage disease plus diabetes or high blood pressure have an increased risk of death or cancer recurrence compared with those colon cancer patients without either condition.
A variety of therapies exist for the severe, debilitating fatigue that often follows cancer treatments.
A novel comprehensive study of prostate cancer tissue has uncovered a completely new gene network driving the disease in patients with castrate-resistant prostate cancer.
Have you had experience in determining the appropriate chemotherapy dose for patients who are obese?
In the October issue, we published an article about the results of a meta-analysis reported at ASCO 2012 that supported the new guidelines that recommend weight-based chemotherapy dosing for obese cancer patients.
Oncology experts from all over the globe arrived in Vienna, Austria, to attend the European Society for Medical Oncology (ESMO) 2012 Congress. Attendance broke all records, with 16,394 delegates, many of them from outside of Europe: 1116 from the United States, 539 from Japan, 479 from China, 292 from Argentina, and 258 from Brazil. Following are some highlights from the Presidential Symposia and papers proffered at the meeting.
Joseph C. Alvarnas, MD, discussed new drugs that might improve outcomes for relapsed/refractory acute lymphoblastic leukemia (ALL) at the National Comprehensive Cancer Network 7th Annual Congress on Hematologic Malignancies.1 Alvarnas is director of medical quality and clinical associate professor at City of Hope Comprehensive Cancer Center in Duarte, California.
The management of relapsed/refractory acute lymphoblastic leukemia (ALL) is a vexing problem and requires extensive, aggressive supportive care throughout the course of therapy, explained Joseph C. Alvarnas, MD, City of Hope Comprehensive Cancer Center, Duarte, California, in a presentation at the National Comprehensive Cancer Network (NCCN) 7th Annual Congress on Hematologic Malignancies.1